3 Penny Stocks to Watch: Tenon Medical, BioXcel Therapeutics, I-Mab

Tenon Medical (TNON), BioXcel Therapeutics (BTAI), and I-Mab (IMAB) are the top 3 penny stocks to watch on August 5, 2025. Tenon Medical has a dollar volume of $344.14 million and a 4.1% decline in stock price. BioXcel Therapeutics has a dollar volume of $149.98 million and an 85.4% surge in stock price. I-Mab has a dollar volume of $116.73 million and an 11.8% rise in stock price. These stocks were picked based on the TipRanks' Penny Stock Screener tool, which helps investors scan stocks based on various parameters such as sector, price target upside, and analyst consensus.

As of July 2, 2025, the TipRanks' Penny Stock Screener tool has identified Tenon Medical (TNON), BioXcel Therapeutics (BTAI), and I-Mab (IMAB) as the top three penny stocks to watch on August 5, 2025. These stocks were selected based on various parameters such as sector, price target upside, and analyst consensus.

Tenon Medical (TNON) has a dollar volume of $344.14 million and experienced a 4.1% decline in stock price. This biotechnology company focuses on developing innovative medical devices and solutions, with a strong emphasis on neuromodulation and neurostimulation technologies.

BioXcel Therapeutics (BTAI) has a dollar volume of $149.98 million and saw an 85.4% surge in stock price. This biopharmaceutical company specializes in the development of targeted immunotherapies for cancer. The company has shown significant growth potential, particularly in its pipeline of bispecific antibodies.

I-Mab (IMAB), a biopharmaceutical company, has a dollar volume of $116.73 million and an 11.8% rise in stock price. I-Mab focuses on immuno-oncology treatments and has successfully priced an underwritten offering of 33.3 million American Depositary Shares (ADSs) at $1.95 each, raising approximately $65 million in gross proceeds [2]. The funds will be used to advance the clinical development of I-Mab's product pipeline, notably a Phase 2 trial for givastomig, a bispecific antibody targeting Claudin 18.2 for treating gastric cancers.

These stocks have shown strong performance and potential for further growth, making them attractive to investors seeking opportunities in the penny stock market. However, it is important to note that penny stocks are inherently riskier investments due to their volatility and lower liquidity. Investors should carefully consider their risk tolerance and conduct thorough research before making investment decisions.

References:
[1] https://www.investopedia.com/the-best-penny-stocks-8778161
[2] https://www.ainvest.com/news/mab-preliminary-financial-results-165-6m-cash-investments-2508/